一种强大的cis-Mendelian随机化方法,适用于药物标发现.
Zhaotong Lin1,2, Wei Pan3
1Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN, 55455, USA. zl23k@fsu.edu.
Nature communications
|July 18, 2024
概括
这项研究引入了cisMR-cML,这是一种用于孟德尔随机化 (MR) 的新方法,可以使用遗传数据强有力的识别因果关系. 它改善了对冠状动脉疾病 (CAD) 等疾病的药物标发现.
科学领域:
- 遗传学 遗传学 是一个
- 流行病学 流行病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 门德尔随机化 (MR) 使用遗传变异作为工具变量 (IVs) 来推断暴露和结果之间的因果关系.
- 传统的MR通常面临着质和链接不平衡 (LD) 的挑战.
- Cis-MR专注于具有cis-单核酸多态性 (cis-SNPs) 的单个基因组区域,为药物标发现提供了一种具有成本效益的方法,特别是使用cis-蛋白质定量特征位点 (cis-pQTLs).
研究的目的:
- 解决现有的 cis-MR 方法关于 pleiotropy 和 LD 的局限性.
- 引入一种新的方法,cisMR-cML,基于强大的因果推理的受约束最大概率.
- 突出使用边际与条件遗传效应以及在cis-MR中选择与暴露相关的SNP的影响.
主要方法:
- 开发cisMR-cML,一种被限制的最大概率方法,用于cis-MR分析.
- 解决违反工具变量假设的理论框架.
- 通过比较cisMR-cML与现有方法的数值模拟进行评估.
- 应用于冠状动脉疾病 (CAD) 药物标识的全蛋白质组分析.
主要成果:
- 在模拟中,cisMR-cML与其他现有的cis-MR方法相比,表现优越.
- 这项研究阐明了当前在建模遗传效应和SNP选择方面的实践的后果.
- 确定了三种潜在的新型药物点:PCSK9,COLEC11和FGFR1.
结论:
- cisMR-cML为cis-MR分析提供了理论上可靠和可靠的方法.
- 这些发现为成本效益高的药物标发现提供了更有效的策略.
- 已确定的目标 (PCSK9, COLEC11, FGFR1) 需要进一步研究CAD治疗开发.
更多相关视频
00:05A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
16.3K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.0K
相关概念视频
01:26Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
01:28Structure-Activity Relationships and Drug Design
697
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
697